Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting
- Authors: Shchinova AM1, Shlevkova GV1, Filatova AY.1, Potekhina AV1, Osokina AK1, Romasov IV1, Zharova EA1, Noeva EA1, Samko AN1, Masenko VP1, Arefieva TI1, Provatorov SI1
-
Affiliations:
- National Medical Research Center of Cardiology
- Issue: Vol 91, No 9 (2019)
- Pages: 10-15
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33575
- DOI: https://doi.org/10.26442/00403660.2019.09.000144
- ID: 33575
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A M Shchinova
National Medical Research Center of Cardiology
Email: alexsasha_shi@inbox.ru
лаборант-исследователь лаб. клеточной иммунологии НИИЭК; ORCID: 0000-0002-3631-5026 Moscow, Russia
G V Shlevkova
National Medical Research Center of Cardiologyаспирант отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
A Yu Filatova
National Medical Research Center of Cardiologyлаборант-исследователь лаб. клеточной иммунологии НИИЭК Moscow, Russia
A V Potekhina
National Medical Research Center of Cardiologyк.м.н., м.н.с. отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
A K Osokina
National Medical Research Center of Cardiologyаспирант отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
I V Romasov
National Medical Research Center of Cardiologyаспирант отд. рентгенэндоваскулярных методов диагностики и лечения НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
E A Zharova
National Medical Research Center of Cardiologyд.м.н., проф., зав. отд-нием легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
E A Noeva
National Medical Research Center of Cardiologyк.м.н., с.н.с. отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
A N Samko
National Medical Research Center of Cardiologyд.м.н., проф., руководитель отд. рентгенэндоваскулярных методов диагностики и лечения НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
V P Masenko
National Medical Research Center of Cardiologyд.м.н., проф., руководитель лаб. нейрогуморальной регуляции сердечно-сосудистых заболеваний Moscow, Russia
T I Arefieva
National Medical Research Center of Cardiologyд.б.н., руководитель лаб. клеточной иммунологии НИИЭК Moscow, Russia
S I Provatorov
National Medical Research Center of Cardiologyд.м.н., в.н.с. отд. легочной гипертензии и заболеваний сердца НИИ клинической кардиологии им. А.Л. Мясникова Moscow, Russia
References
- Гребенщикова И.А. Эпидемиология ишемической болезни сердца и значение показателей периферического атеросклероза и функционального состояния почек в развитии коронарной болезни сердца у мужчин. Современные проблемы науки и образования. 2011;(5).
- Williams T.N, Zhang C.X, Game B.A, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal - regulated kinase pathway:: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2004;24:61-6. doi: 10.1161/01.ATV.0000104014.24367.16
- Wågsäter D, Zhu C, Björkegren J, Skogsberg J, Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med. 2011;28:247-53. doi: 10.3892/ijmm.2011.693
- Dabek J, Glogowska-Ligus J, Szadorska B. Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients. J Postgrad Med. 2013;59:115-20. doi: 10.4103/0022-3859.113836
- Guo C, et al. Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9. Exp Ther Med. 2014;7:1177-80. doi: 10.3892/etm.2014.1565
- Szalai A.J, Agrawal A, Greenhough T.J, Volanakis, J.E. C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res. 1997;16:127-36. doi: 10.1007/BF02786357
- Szmitko P.E, Verma S. C-reactive protein and statins: IL-8 as a molecular link? Clin Sci Lond Engl. 2005;108:493-5. doi: 10.1042/CS20050093
- Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol. 2005;25:2216-21. doi: 10.1161/01.ATV.0000183718.62409.ea
- Devaraj S, Xu D.Y, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404. doi: 10.1161/01.cir. 0000052617.91920.fd
- Mirjanic-Azaric B, et al. Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses. Clin Biochem. 2013;46:1526-31. doi: 10.1016/j.clinbiochem.2013.06.006
- Ferri C, et al. C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des. 2007;13:1631-45. doi: 10.2174/138161207780831301
- Libby P, Ridker P.M. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100:1148-50. doi: 10.1161/01.cir.100.11.1148
- Ridker P.M, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8. doi: 10.1056/NEJMoa042378
- Takemoto M, Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-9. doi: 10.1161/hq1101.098486
- Mausner-Fainberg K, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T-cells. Atherosclerosis. 2008;197:829-39. doi: 10.1016/j.atherosclerosis.2007.07.031
- Nissen S.E, et al. Effect of intensive compared with moderate lipid - lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-80. doi: 10.1001/jama.291.9.1071
- Albert M.A, Danielson E, Rifai N, Ridker P.M. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70. doi: 10.1001/jama.286.1.64
- Kim J-S, et al. Efficacy of high - dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3:332-9. doi: 10.1016/j.jcin.2009.11.021
- Isaacsohn J.L, et al. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000;86:250-2. doi: 10.1016/s0002-9149(00)00872-9
- La Rosa J.C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. doi: 10.1056/NEJMoa050461
- Рекомендации по лечению стабильной ишемической болезни сердца ESC. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines
- Kinlay S, et al. High - dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-6. doi: 10.1161/01.CIR.0000091404.09558.AF
- Loppnow H, et al. Statins potently reduce the cytokine - mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med. 2011;15:994-1004. doi: 10.1111/j.1582-4934.2010.01036.x
- Miyazaki Y, et al. Effect of statins on atherogenic serum amyloid A and α1-antitrypsin low - density lipoprotein complexes. Int J Cardiol. 2016;225:332-6. doi: 10.1016/j.ijcard.2016.09.116
- Ridker P.M. High - sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-8. doi: 10.1161/01.cir. 103.13.1813
- Park D-W, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug - eluting stent implantation. Circulation. 2009;120:1987-95. doi: 10.1161/CIRCULATIONAHA.109.876763
- Delhaye C, et al. Long - term prognostic value of preprocedural C-reactive protein after drug - eluting stent implantation. Am J Cardiol. 2010;105:826-32. doi: 10.1016/j.amjcard.2009.10.064
- Iijima R, et al. Pre - procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart Br Card Soc. 2009;95:107-12. doi: 10.1136/hrt.2008.153635
- Park D-W, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug - eluting stent implantation. Heart Br Card Soc. 2007;93:1087-92. doi: 10.1136/hrt.2006.099762
- Ridker P.M, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet Lond Engl. 2017. doi: 10.1016/S0140-6736(17)32814-3.
- Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T-cells in patients with acute coronary syndromes. Eur Heart J. 2006;27:2530-7. doi: 10.1093/eurheartj/ehl222
- Kim Y.C, Kim K.K, Shevach E.M. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor - beta signal transduction. Immunology. 2010;130:484-93. doi: 10.1111/j.1365-2567.2010.03269.x
- Meng X, et al. Statins induce the accumulation of regulatory T-cells in atherosclerotic plaque. Mol Med Camb Mass. 2012;18:598-605. doi: 10.2119/molmed.2011.00471
- Filatova A.Yu, Kuznetsova G.V, Shchinova A.M, Osokina A.K, Potekhina A.V, et al. Influence of short - term intensive atorvastatin therapy on lymphocyte and monocyte subpopulations and CCR2, CCR5, CX3CR1 and TLR4 expression in blood of patients with stable angina. 85th EAS Congress, Prague, 2016.
- Nabatov A.A, Pollakis G, Linnemann T, Paxton W.A, de Baar M.P. Statins disrupt CCR5 and RANTES expression levels in CD4(+) T-lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PloS One. 2007;(2):e470. doi: 10.1371/journal.pone.0000470
- Veillard N.R, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51-8. doi: 10.1016/j.atherosclerosis.2005.10.015
- Martínez-González J, Alfón J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis. 2001;159:27-33. doi: 10.1016/S0021-9150(01)00469-5
![](/img/style/loading.gif)